Page 138 - 《中国药房》2021年第1期

Drug Metabolism Reviews，2009，41（S3）：82. chrome P450 3A4 and CYP3A5-catalyzed bioactivation
[57] POSOCCO B，BUZZO M，GIODINI L，et al. Analytical of lapatinib[J]. Drug Metab Dispos，2016，44（10）：
aspects of sunitinib and its geometric isomerism towards 1584-1597.
therapeutic drug monitoring in clinical routine[J]. J Pharm [70] FUMOLEAU P，KOCH KM，BRAIN E，et al. A phase Ⅰ
Biomed Anal，2018. DOI：10.1016/j.jpba.2018.08.013. pharmacokinetics study of lapatinib and tamoxifen in me-
[58] 王童，李彩霞，陈晓晨，等.慢性髓系白血病患者尼洛替尼 tastatic breast cancer EORTC 10053 Lapatam study[J].
血药浓度与临床疗效相关性的研究[J].中国实验血液学 Breast，2014，23（5）：663-669.
杂志，2018，26（1）：116-120. [71] BURRIS HA，TAYLOR CW，JONES SF，et al. A phase Ⅰ
[59] KAGAN M，TRAN P，FISCHER V，et al. Safety，pharma- and pharmacokinetic study of oral lapatinib administered
cokinetics（PK），metabolism，and mass balance of [14C]- once or twice daily in patients with solid malignancies[J].
AMN107，a novel aminopyrimidine inhibitor of Bcr-Abl Clin Cancer Res，2009，15（21）：6702-6708.
tyrosine kinase，in healthy subjects[J]. Blood，2005. DOI： [72] COKER SA，HURWITZ HI，SHARMA S，et al. The
org/10.1182/blood.V106.11.4887.4887. efects of lapatinib on cardiac repolarization：results from a
[60] TIAN XB，ZHANG HF，HEIMBACH T，et al. Clinical placebo controlled，single sequence，crossover study in pa-
pharmacokinetic and pharmacodynamic overview of nilo- tients with advanced solid tumors[J]. Cancer Chemother
tinib，a selective tyrosine kinase inhibitor[J]. J Clin Phar- Pharmacol，2019，84（2）：383-392.
macol，2018，58（12）：1533-1540. [73] BENCE AK，ANDERSON EB，HALEPOTA MA，et al.
[61] GILES FJ，YIN OQ，SALLAS WM，et al. Nilotinib popu- Phase Ⅰ pharmacokinetic studies evaluating single and
lation pharmacokinetics and exposure-response analysis multiple doses of oral GW572016，a dual EGFR-ErbB2 in-
in patients with imatinib-resistant or -intolerant chronic hibitor，in healthy subjects[J]. Invest New Drugs，2005，23
myeloid leukemia[J]. Eur J Clin Pharmacol，2013，69（4）： （1）：39-49.
813-823. [74] XU F，LEE K，XIA W，et al. Administration of lapatinib
[62] LARSON RA，YIN OQ，HOCHHAUS A，et al. Popula- with food increases its plasma concentration in Chinese
tion pharmacokinetic and exposure-response analysis of patients with metastatic breast cancer：a prospective phase
nilotinib in patients with newly diagnosed Ph + chronic Ⅱ study[J]. Oncologist，2020，25（9）：e1286-e1291.
myeloid leukemia in chronic phase[J]. Eur J Clin Pharma- [75] KARBOWNIK A，SZAŁEK E，SOBAŃSKA K，et al. The
col，2012，68（5）：723-733. concomitant use of lapatinib and paracetamol：the risk of
[63] TANAKA C，YIN OQ，SMITH T，et al. Effects of ri- interaction[J]. Invest New Drugs，2018，36（5）：819-827.
fampin and ketoconazole on the pharmacokinetics of nilo- [76] LOU D，CUI X，BAO SS，et al. Effects of ketoconazole，
tinib in healthy participants[J]. J Clin Pharmacol，2011，51 voriconazole，and itraconazole on the pharmacokinetics of
（1）：75-83. apatinib in rats[J]. Drug Dev Ind Pharm，2019，45（4）：
[64] YIN OQ，GALLAGHER N，LI A，et al. Effect of grape- 689-693.
fruit juice on the pharmacokinetics of nilotinib in healthy [77] LIU XY，ZHANG YF，CHEN Q，et al. Pharmacokinetic
participants[J]. J Clin Pharmacol，2010，50（2）：188-194. drug interactions of apatinib with rifampin and itraco-
[65] ZHANG HF，SHENG J，KO JH，et al. Inhibitory effect of nazole[J]. J Clin Pharmacol，2018，58（3）：347-356.
single and repeated doses of nilotinib on the pharmacoki- [78] GUAN SX，SHI W，ZHAO ZR，et al. Determination of
netics of CYP3A substrate midazolam[J]. J Clin Pharma- apatinib and its three active metabolites by UPLC-MS/MS
col，2015，55（4）：401-408. in a phase Ⅳ clinical trial in NSCLC patients[J]. Bioanaly-
[66] YIN OQ，GILES FJ，BACCARANI M，et al. Concurrent sis，2019，11（22）：2049-2060.
use of proton pump inhibitors or H2 blockers did not ad- [79] 范芳，余炜，刘捷，等.真实世界中阿帕替尼血药浓度研
versely affect nilotinib effcacy in patients with chronic 究[J].临床合理用药，2020，13（2）：117-118.
myeloid leukemia[J]. Cancer Chemother Pharmacol， [80] LI J，ZHAO XM，CHEN L，et al. Safety and pharmacoki-
2012，70（2）：345-350. netics of novel selective vascular endothelial growth fac-
[67] YIN OQ，BÉDOUCHA V，MCCULLOCH T，et al. Ef- tor receptor-2 inhibitor YN968D1 in patients with ad-
fects of famotidine or an antacid preparation on the phar- vanced malignancies[J]. BMC Cancer，2010. DOI：10.
macokinetics of nilotinib in healthy volunteers[J]. Cancer 1186/1471-2407-10-529.
Chemother Pharmacol，2013，71（1）：219-226. [81] SCOTT LJ. Apatinib：a review in advanced gastric cancer
[68] LIAO JL，GALLAS M，PEGRAM M，et al. Lapatinib： and other advanced cancers[J]. Drugs，2018，78（7）：747-
new opportunities for management of breast cancer[J]. 758.
Breast Cancer：Dove Med Press，2010. DOI：10.2147/ （收稿日期：2020-07-22 修回日期：2020-12-10）
BCTT.S5929. （编辑：罗 瑞）
[69] TOWLES JK，CLARK RN，WAHLIN MD，et al. Cyto-

·128 · China Pharmacy 2021 Vol. 32 No. 1 中国药房 2021年第32卷第1期